Moolec Science Stock Price, News & Analysis

Moolec Science (NASDAQ:MLEC), a biotechnology company focused on engineering plants and microbes for protein solutions, announced three significant developments. First, the company received regulatory approval from SENASA in Argentina for its safflower GLASO technology, enabling expansion of its GLA-enriched safflower crop production. Second, Moolec has doubled its U.S. safflower acreage compared to last year, strengthening its supply capabilities for the pet food and human nutrition markets.

Additionally, the company appointed Valeria Falottico as CFO, bringing over 20 years of financial expertise. Moolec also completed the integration of Mycofood™, its fungal-based protein platform, which is currently developing products for evaluation by food industry partners in North America and Europe.

Moolec Science (NASDAQ:MLEC) has secured a crucial U.S. patent for its Piggy Sooy™ technology, a groundbreaking soybean engineered to produce high levels of porcine hemeproteins in seeds. The patent, valid until 2042, covers plants, seeds, development methods, and derived food compositions. Initial field trials showed impressive results with over 20% animal protein content in the total soluble protein fraction. The technology demonstrates significant environmental advantages: one acre of Piggy Sooy™ can produce protein equivalent to 10 pigs while using 35x less land, 8x less water, and generating 60x less CO2 emissions. The USDA-APHIS has already confirmed the technology poses no additional plant pest risk compared to conventional soybeans, marking a key milestone toward commercialization. This patent is part of Moolec's broader strategy, with over fifteen global patent applications protecting their Molecular Farming innovations.

Moolec Science (NASDAQ:MLEC) has successfully completed a strategic business combination with Bioceres Group, Gentle Technologies Corp, and Nutrecon LLC. The merger was approved by shareholders with 98% of votes in favor. Under the deal terms, Bioceres Group shareholders received ~6.9M Moolec shares, while Nutrecon and Gentle Tech shareholders got ~0.65M shares and 0.5M private warrants at $20 strike price. The company appointed Alejandro Antalich as CEO, bringing 20+ years of biotech leadership experience. The combined entity maintains the Moolec Science name and NASDAQ listing (MLEC, MLECW). This merger expands Moolec's capabilities across food ingredients, ag-biologicals, precision fermentation, and biomaterials, integrating products like Piggy Sooy, GLASO, Mycofood, and biological inputs under brands including Rizobacter, ProFarm, and HB4.

Moolec Science (NASDAQ:MLEC) has announced the implementation of a 1-for-10 reverse stock split, effective May 14, 2025, at 8:30 AM Eastern Time. The consolidation will reduce the company's outstanding shares from approximately 40 million to 4 million shares, with no change to the par value per share. The stock will continue trading on NASDAQ under the symbol "MLEC" with a new CUSIP code (L64875 120), while warrants will maintain their "MLECW" symbol. Shareholders are not required to take any action, as positions will be automatically adjusted. The reverse split follows resolutions passed at the extraordinary general meeting and board meeting on April 22, 2025.

Moolec Science (NASDAQ:MLEC) has announced a transformational all-stock Business Combination Agreement with Bioceres Group and other entities. The deal involves Moolec issuing up to 87 million new shares and 5 million warrants to acquire Bioceres Group, Nutrecon , and Gentle Technologies Corp.

The combined entity will control a portfolio of over 800 patents and 550 product registrations, representing more than half a billion dollars in annual sales across 50+ countries. The transaction positions Moolec as a comprehensive agricultural technology company, integrating molecular farming, biological inputs, and climate-resilient seeds.

Key highlights include:

• Continued development of molecular farming products (Piggy Sooy™, GLASO™)
• Integration of biological agricultural solutions through Bioceres Group
• Expansion into R&D and CDMO services under Agrality® and Synbio Powerlabs®
• Development of emerging technologies in biomaterials and farm equipment

The transaction is expected to close in Q2 2025, subject to shareholder approval and other conditions. CEO Gastón Paladini will step down following the April 22, 2025 Extraordinary General Meeting.

Moolec Science SA (NASDAQ:MLEC) has received a Nasdaq Staff Determination Letter on March 11, 2025, indicating non-compliance with listing requirements as its stock price remained below $1.00 for over 30 consecutive business days since September 10, 2024. The company is not eligible for a second 180-day compliance period due to not meeting the $5,000,000 minimum stockholders' equity requirement.

On March 13, 2025, Moolec appealed the determination and plans to present a compliance strategy involving a reverse share split. The appeal temporarily halts any delisting actions. The Board of Directors has resolved to convene an extraordinary shareholders meeting to vote on the reverse share split. Without securing an extension from the Hearings Panel or achieving compliance, the company's ordinary shares and warrants face potential delisting from Nasdaq.

Moolec Science SA (NASDAQ:MLEC) has received USDA approval for the first genetically modified pea in history. The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) completed its Regulatory Status Review for Moolec's genetically engineered peas that produce iron through bovine meat proteins. This marks Moolec's third USDA-APHIS regulatory clearance in 18 months, following approvals for genetically engineered safflower and soybean.

The GE peas produce high yields of bovine myoglobin, boosting iron content and offering a plant-based iron source. This innovation has the potential to impact both the food ingredient market and the $65 billion pea industry. The approval validates Moolec's strategic approach and commitment to sustainable food production through science and innovation.

Moolec Science SA (NASDAQ:MLEC) reported its Business Update for Q4 FY2024 ended June 30, 2024. Key highlights include:

1. GLASO™: Secured an offtake agreement with a major global CPG food and pet food company and an R&D collaboration with Bunge. Significant advancements in upstream and downstream processes.

2. Piggy Sooy™: Field trials in three US locations progressing for product development, seed increase, and regulatory data gathering.

3. TSP Valorasoy™: Trials for enhanced Valorasoy 2.0 products showed encouraging results.

4. Financials: Revenue & other income of ~$6M for FY 2024, driven by soy protein ingredient business. Prudent cash burn in line with company growth.

The company highlighted the USDA-APHIS approval for PiggySooy™ as a pivotal moment in Molecular Farming. Moolec is preparing for the commercialization of GLASO™ and advancing its product pipeline.

Moolec Science SA (NASDAQ:MLEC), a science-based food ingredient company, has announced it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on October 2, 2024, before market open. The company will host a live Conference Call and webcast on the same day at 08:30 AM ET.

The call will feature CEO Gastón Paladini, CFO José López Lecube, and Chief Science Officer Amit Dhingra. It will include a presentation viewable during the webcast, with a replay and PDF version available afterwards on Moolec's Investor Relations website.

Participants can join via the provided Zoom link or dial-in numbers. The webinar ID is 915 9750 1131, with passcode 799765. International dial-in numbers are also available.